Lan Dang is currently a senior scientist in the CNS Research unit (RU) at at Alnylam Pharmaceuticals, where she focuses on using cells derived from people with neurological disorders for neurological disease modeling and to support multiple pre-clinical and platform development programs. Before joining Alnylam, Dr. Dang was a member of the Movement Disorder RU at Biogen, where she participated in projects specializing in high-content assay development, neurological disease modeling in patient-derived cells, and the development of biomarkers for early PD pre-clinical programs. Prior to joining the Movement Disorders RU, Dr. Dang conducted postdoctoral studies at Biogen to identify molecular mechanisms of vascular regeneration following kidney tissue injury. This project led to the discovery of several targets, one of which, surprisingly, pioneered a new research program for PD.